Pomerantz Law Firm Probes Potential Securities Fraud at Soleno Therapeutics

In a significant move for investors, the Pomerantz Law Firm is investigating potential claims against Soleno Therapeutics, Inc. (NASDAQ: SLNO), focusing on allegations of securities fraud and unlawful business practices. The investigation stems from serious concerns raised about the Company's sole product, Vykat XR, which has been described by a market analyst as overpriced and possibly unsafe for children.

On August 15, 2025, Scorpion Capital released a report that criticized Vykat XR, leading to a substantial decline in Soleno's stock price, which dropped by $5.73 per share, representing a 7.41% decrease. This downward movement raised alarms among investors regarding the Company's stability and the transparency of its business operations.

The situation escalated further when Soleno's management revealed on November 4, 2025, during its quarterly earnings call, that the discontinuation rate of Vykat XR due to adverse effects was approximately 8% by the end of the third quarter of fiscal 2025. This admission indicated a disruption in the launch rhythm of Vykat XR, which Soleno's CEO attributed to the fallout from the Scorpion report.

Consequently, the adverse market reaction saw Soleno’s stock plummet by an alarming $16.98 per share, a staggering 26.59% drop, closing at $46.87 on November 5, 2025. The fallout from these revelations puts into question the Company's commitment to its customers and its operational integrity, prompting the investigation by Pomerantz LLP into whether Soleno’s executives acted appropriately in light of these challenges.

Pomerantz LLP, a well-respected law firm with a rich history in advocating for victims of securities fraud and corporate malfeasance, emphasized its ongoing commitment to fighting for investors’ rights. Established by the esteemed Abraham L. Pomerantz, the firm has been involved in numerous high-stakes cases that have resulted in substantial recoveries for affected investors.

Investors who feel impacted by Soleno's actions are encouraged to contact Pomerantz to inquire about participating in the class action claims. Danielle Peyton, an attorney with Pomerantz, is the primary contact for further inquiries, available at [email protected] or at 646-581-9980.

This ongoing situation underscores the importance of due diligence in investing, especially in biotech firms whose products may significantly affect vulnerable populations, such as children. As Soleno Therapeutics navigates through this challenging chapter, stakeholders will be watching closely to see how these investigations unfold and what implications they may have on investment outcomes moving forward.

With Pomerantz at the helm of this investigation, investors can remain hopeful that their concerns will be addressed adequately and that accountability will be sought against any potential wrongdoing within the corporate structure of Soleno Therapeutics.